

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086371 A2

(51) International Patent Classification⁷: **A61K 31/00**,
31/42, 31/426, A61P 9/00, 37/06, A61K 31/4178, 31/421,
A61P 1/16, 25/28, G01N 33/80, A61K 31/437, 31/422,
A61P 7/02, 25/00

& Development, Nagoya Laboratories Pfizer Inc., 5-2
Takeoyo, Aichi 470-2393 (JP).

(21) International Application Number: PCT/IB03/01310

(22) International Filing Date: 3 April 2003 (03.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/372,364 12 April 2002 (12.04.2002) US

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor
Road, Morris Plains, NJ 07950 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for JP only*): **PFIZER PHARMACEUTI-
CALS INC.** [JP/JP]; Mitsui Building, 1-1, Nishi-shinjuku
2-chome, Shinjuku-ku, Tokyo 163-0461 (JP).

(71) Applicant (*for all designated States except JP, US*):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SHIMOJO, Masato**
[JP/JP]; Pfizer Global Research and Development, Nagoya
Laboratoires Pfizer Inc., 5-2 Taketoyo, Aichi 470-2393
(JP). **TANIGUCHI, Kana** [JP/JP]; Pfizer Global Research

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES

(57) Abstract: The present invention relates to the use of an EP4 receptor ligand in the manufacture of a medicament for the treat-
ment of IL-6 involved diseases. Also relates to the assay comprising: culturing peripheral whole blood with a test compound; and
determining the effect of the compound on PGE2-induced whole blood cells activation.



WO 03/086371 A2